{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:41:53Z","timestamp":1756464113699},"reference-count":44,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1248\/bpb.b18-00408","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T17:37:11Z","timestamp":1548956231000},"page":"164-172","source":"Crossref","is-referenced-by-count":6,"title":["Augmentation of Lipopolysaccharide-Induced Production of IL-1\u03b1 and IL-1\u03b2 in Mice Given Intravenous Zoledronate (a Nitrogen-Containing Bisphosphonate) and Its Prevention by Clodronate (a Non-nitrogen-containing Bisphosphonate)"],"prefix":"10.1248","volume":"42","author":[{"given":"Hikari","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanan","family":"Bando","sequence":"additional","affiliation":[{"name":"Division of Orthodontics and Dentofacial Orthopedics, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tada","sequence":"additional","affiliation":[{"name":"Division of Oral Molecular Regulation, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Kiyama","sequence":"additional","affiliation":[{"name":"Division of Advanced Prosthetic Dentistry, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Oizumi","sequence":"additional","affiliation":[{"name":"Division of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Funayama","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dentistry, Tsurumi University School of Dental Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Division of Oral Molecular Regulation, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Fleisch H. Diphosphonates: history and mechanisms of actions. <i>Metab. Bone Dis. Relat. Res.<\/i>, <b>3<\/b>, 279\u2013287 (1981).","DOI":"10.1016\/0221-8747(81)90044-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rogers MJ, Crockett JC, Coxon FP, M\u00f6nkk\u00f6nen J. Biochemical and molecular mechanisms of action of bisphosphonates. <i>Bone<\/i>, <b>49<\/b>, 34\u201341 (2011).","DOI":"10.1016\/j.bone.2010.11.008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Endo Y, Kumamoto H, Nakamura M, Sugawara S, Takano-Yamamoto T, Sasaki K, Takahashi T. Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the jaw (BRONJ). <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 739\u2013750 (2017).","DOI":"10.1248\/bpb.b16-01020"},{"key":"4","unstructured":"4) Geddes AD, D\u2019Souza SM, Ebetino FH, Kenneth JI. Bisphosphonates: structure\u2013activity relationships and therapeutic implications. <i>Bone and Mineral Research<\/i>. (Heershe NM, Kanis JK ed). Vol. 8, Elsevier Science BV, Amsterdam, Holland, pp. 265\u2013306 (1994)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V. The acute phase response after bisphosphonate administration. <i>Calcif. Tissue Int.<\/i>, <b>41<\/b>, 326\u2013331 (1987).","DOI":"10.1007\/BF02556671"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Adami S, Zamberlan N. Adverse effects of bisphosphonate: a comparative review. <i>Drug Saf.<\/i>, <b>14<\/b>, 158\u2013170 (1996).","DOI":"10.2165\/00002018-199614030-00003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) H\u00f6gler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. <i>J. Pediatr.<\/i>, <b>145<\/b>, 701\u2013704 (2004).","DOI":"10.1016\/j.jpeds.2004.06.066"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud RJ, Tebben PJ. Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. <i>Osteoporos. Int.<\/i>, <b>27<\/b>, 2379\u20132382 (2016).","DOI":"10.1007\/s00198-016-3528-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. <i>Bone<\/i>, <b>35<\/b>, 231\u2013234 (2004).","DOI":"10.1016\/j.bone.2004.03.008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from MOBILE study. <i>Ann. Rheum. Dis.<\/i>, <b>65<\/b>, 654\u2013661 (2006).","DOI":"10.1136\/ard.2005.044958"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Endo Y, Nakamura M, Kikuchi T, Shinoda H, Takeda Y, Nitta Y, Kumagai K. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes and osteoclasts <i>in vivo<\/i>. <i>Calcif. Tissue Int.<\/i>, <b>52<\/b>, 248\u2013254 (1993).","DOI":"10.1007\/BF00298728"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Sugawara S, Shibazaki M, Takada H, Kosugi H, Endo Y. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor \u03b1 in mice. <i>Br. J. Pharmacol.<\/i>, <b>125<\/b>, 735\u2013740 (1998).","DOI":"10.1038\/sj.bjp.0702151"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yamaguchi K, Motegi K, Iwakura Y, Endo Y. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. <i>Br. J. Pharmacol.<\/i>, <b>130<\/b>, 1646\u20131654 (2000).","DOI":"10.1038\/sj.bjp.0703460"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Deng X, Yu Z, Funayama H, Shoji N, Sasano T, Iwakura Y, Sugawara S, Endo Y. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. <i>Toxicol. Appl. Pharmacol.<\/i>, <b>213<\/b>, 64\u201373 (2006).","DOI":"10.1016\/j.taap.2005.09.005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shikama Y, Nagai Y, Okada S, Oizumi T, Shimauchi H, Sugawara S, Endo Y. Pro-IL-1\u03b2 accumulation in macrophages by alendronate and its prevention by clodronate. <i>Toxicol. Lett.<\/i>, <b>199<\/b>, 123\u2013128 (2010).","DOI":"10.1016\/j.toxlet.2010.08.013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Deng X, Yu Z, Funayama H, Yamaguchi K, Sasano T, Sugawara S, Endo Y. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNF\u03b1, macrophages, and T-cells. <i>Int. Immunopharmacol.<\/i>, <b>7<\/b>, 152\u2013161 (2007).","DOI":"10.1016\/j.intimp.2006.09.009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Funayama H, Mayanagi H, Takada H, Endo Y. Elevation of histidine decarboxylase activity in the mandible of mice by <i>Prevotella intermedia<\/i> lipopolysaccharide and its augmentation by an aminobisphosphonate. <i>Arch. Oral Biol.<\/i>, <b>45<\/b>, 787\u2013795 (2000).","DOI":"10.1016\/S0003-9969(00)00039-X"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Oizumi T, Yamaguchi K, Funayama H, Kuroishi T, Kawamura H, Sugawara S, Endo Y. Necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their inhibition by clodronate (a non-NBP) in mice: potential for utilization of clodronate as a combination drug with an NBP. <i>Basic Clin. Pharmacol. Toxicol.<\/i>, <b>104<\/b>, 384\u2013392 (2009).","DOI":"10.1111\/j.1742-7843.2008.00374.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Shima K, Tsuchiya M, Oizumi T, Takano-Yamamoto T, Sugawara S, Endo Y. Inflammatory effects of nitrogen-containing bisphosphonates (N-BPs): modulation by non-N-BPs. <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 25\u201333 (2017).","DOI":"10.1248\/bpb.b16-00521"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Endo Y, Shibazaki M, Yamaguchi K, Nakamura M, Kosugi H. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. <i>Br. J. Pharmacol.<\/i>, <b>126<\/b>, 903\u2013910 (1999).","DOI":"10.1038\/sj.bjp.0702367"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kiyama T, Tsuchiya M, Okada S, Oizumi T, Yamaguchi K, Sasaki K, Sugawara S, Endo Y. Phosphonocarboxylates can protect mice against the inflammatory and necrotic side effects of nitrogen-containing bisphosphonates by inhibiting their entry into cells <i>via<\/i> phosphate transporters. <i>Biol. Pharm. Bull.<\/i>, <b>39<\/b>, 712\u2013720 (2016).","DOI":"10.1248\/bpb.b15-00770"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Okada S, Kiyama T, Sato E, Tanaka Y, Oizumi T, Kuroishi T, Takahashi T, Sasaki K, Sugawara S, Endo Y. Inhibition of phosphate transporters ameliorate the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice. <i>Tohoku J. Exp. Med.<\/i>, <b>231<\/b>, 145\u2013158 (2013).","DOI":"10.1620\/tjem.231.145"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Shima K, Nemoto W, Tsuchiya M, Tan-No K, Takano-Yamamoto T, Sugawara S, Endo Y. The bisphosphonates clodronate and etidronate exert analgesic effects by acting on glutamate- and\/or ATP-related pain transmission pathways. <i>Biol. Pharm. Bull.<\/i>, <b>39<\/b>, 770\u2013777 (2016).","DOI":"10.1248\/bpb.b15-00882"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kato Y, Hiasa M, Ichikawa R, Hasuzawa N, Kadowaki A, Iwatsuki K, Shima K, Endo Y, Kitahara Y, Inoue T, Nomura M, Omote H, Moriyama Y, Miyaji T. Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>114<\/b>, E6297\u2013E6305 (2017).","DOI":"10.1073\/pnas.1704847114"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K. Factors associated with acute-phase response of bisphosphonate-na\u00efve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate of ibandronate. <i>Osteoporos. Int.<\/i>, <b>28<\/b>, 1995\u20132002 (2017).","DOI":"10.1007\/s00198-017-3992-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Monma Y, Funayama H, Mayanagi H, Endo Y. Effects of weekly administrations of alendronate\u2009+\u2009clodronate on young mouse tibia: localized action at the proximal growth plate. <i>Calcif. Tissue Int.<\/i>, <b>74<\/b>, 115\u2013121 (2004).","DOI":"10.1007\/s00223-002-2156-5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Funayama H, Ohsako M, Monma Y, Mayanagi H, Sugawara S, Endo Y. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. <i>Calcif. Tissue Int.<\/i>, <b>76<\/b>, 448\u2013457 (2005).","DOI":"10.1007\/s00223-004-0180-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Yu Z, Funayama H, Deng X, Kuroishi T, Sasano T, Sugawara S, Endo Y. Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model. <i>Basic Clin. Pharmacol. Toxicol.<\/i>, <b>97<\/b>, 222\u2013229 (2005).","DOI":"10.1111\/j.1742-7843.2005.pto_138.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Kiyama T, Okada S, Tanaka Y, Kim S, Bando K, Hasegawa M, Yamaguchi K, Takano-Yamamoto T, Sasaki K, Sugawara S, Endo Y. Inflammatory and necrotic effects of minodronate, a nitrogen-containing bisphosphonates, in mice. <i>Tohoku J. Exp. Med.<\/i>, <b>230<\/b>, 141\u2013149 (2013).","DOI":"10.1620\/tjem.230.141"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Dinarello CA. A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation. <i>Eur. J. Immunol.<\/i>, <b>41<\/b>, 1203\u20131217 (2011).","DOI":"10.1002\/eji.201141550"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. <i>Bone<\/i>, <b>49<\/b>, 710\u2013716 (2011).","DOI":"10.1016\/j.bone.2011.07.020"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Virkki LV, Biber J, Murer H, Forster IC. Phosphate transporters: a tale of two solute carrier families. <i>Am. J. Physiol. Renal Physiol.<\/i>, <b>293<\/b>, F643\u2013F654 (2007).","DOI":"10.1152\/ajprenal.00228.2007"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Miyamoto K, Haito-Sugino S, Kuwahara S, Ohi A, Nomura K, Ito M, Kuwahata M, Kido S, Tatsumi S, Kaneko I, Segawa H. Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. <i>J. Pharm. Sci.<\/i>, <b>100<\/b>, 3719\u20133730 (2011).","DOI":"10.1002\/jps.22614"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Fujita T, Ohue M, Fujii Y, Miyauchi A, Takagi Y. Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. <i>J. Bone Miner. Metab.<\/i>, <b>27<\/b>, 234\u2013239 (2009).","DOI":"10.1007\/s00774-009-0035-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kim S, Seiryu M, Okada S, Kuroishi T, Takano-Yamamoto T, Sugawara S, Endo Y. Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone. <i>Eur. J. Pharmacol.<\/i>, <b>699<\/b>, 14\u201322 (2013).","DOI":"10.1016\/j.ejphar.2012.11.031"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Debrek L, Thor P. Glutamate NMDA receptors in pathology and pharmacotherapy of selected nervous system diseases. <i>Postepy Hig. Med. Dosw.<\/i>, <b>65<\/b>, 338\u2013346 (2011).","DOI":"10.5604\/17322693.946637"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Omote H, Moriyama Y. Vesicular neurotransmitter transporters: an approach for studying transporters with purified proteins. <i>Physiology<\/i>, <b>28<\/b>, 39\u201350 (2013).","DOI":"10.1152\/physiol.00033.2012"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced \u03b3\u03b4T-cell proliferation and activation <i>in vitro<\/i>. <i>J. Bone Miner. Res.<\/i>, <b>19<\/b>, 278\u2013288 (2004).","DOI":"10.1359\/JBMR.0301230"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood \u03b3\u03b4T cells in response to aminobisphosphonates is inhibited by statins. <i>Clin. Exp. Immunol.<\/i>, <b>139<\/b>, 101\u2013111 (2005).","DOI":"10.1111\/j.1365-2249.2005.02665.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Srivastava T, Haney CJ, Alon US. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. <i>J. Bone Miner. Res.<\/i>, <b>24<\/b>, 334\u2013337 (2009).","DOI":"10.1359\/jbmr.081016"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. <i>Osteoporos. Int.<\/i>, <b>22<\/b>, 2337\u20132345 (2011).","DOI":"10.1007\/s00198-010-1448-2"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Billington EO, Horne A, Gamble GD, Maslowski K, House M, Reid IR. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. <i>Osteoporos. Int.<\/i>, <b>28<\/b>, 1867\u20131874 (2017).","DOI":"10.1007\/s00198-017-3960-0"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. <i>Pharmacotherapy<\/i>, <b>24<\/b>, 195\u2013197 (2004).","DOI":"10.1592\/phco.24.2.195.33143"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Goossens N, Spahr L, Rubbia-Brandt L. Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report. <i>J. Hepatol.<\/i>, <b>59<\/b>, 1139\u20131142 (2013).","DOI":"10.1016\/j.jhep.2013.06.003"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/2\/42_b18-00408\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T15:43:00Z","timestamp":1573832580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/2\/42_b18-00408\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b18-00408","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}